UBS Group’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,463
| Closed | -$3.17K | – | 10332 |
|
|
2023
Q1 | $3.17K | Buy |
5,463
+508
| +10% | +$404 | ﹤0.01% | 8363 |
|
|
2022
Q4 | $3.47K | Buy |
4,955
+2,158
| +77% | +$3.51K | ﹤0.01% | 9508 |
|
|
2022
Q3 | $8K | Sell |
2,797
-690
| -20% | -$2.61K | ﹤0.01% | 8804 |
|
|
2022
Q2 | $16K | Buy |
3,487
+1,629
| +88% | +$7.15K | ﹤0.01% | 7243 |
|
|
2022
Q1 | $13K | Sell |
1,858
-150
| -7% | -$871 | ﹤0.01% | 8112 |
|
|
2021
Q4 | $14K | Buy |
+2,008
| New | +$20.6K | ﹤0.01% | 8389 |
|
|
2021
Q3 | – | Sell |
-260
| Closed | -$5K | – | 10387 |
|
|
2021
Q2 | $5K | Buy |
260
+97
| +60% | +$1.81K | ﹤0.01% | 8600 |
|
|
2021
Q1 | $4K | Buy |
+163
| New | +$4.13K | ﹤0.01% | 8453 |
|
|
2020
Q4 | – | Sell |
-112
| Closed | -$2K | – | 8933 |
|
|
2020
Q3 | $2K | Sell |
112
-156
| -58% | -$2.93K | ﹤0.01% | 7717 |
|
|
2020
Q2 | $4K | Sell |
268
-307
| -53% | -$4.79K | ﹤0.01% | 7495 |
|
|
2020
Q1 | $8K | Sell |
575
-33
| -5% | -$670 | ﹤0.01% | 7103 |
|
|
2019
Q4 | $18K | Sell |
608
-202
| -25% | -$4.83K | ﹤0.01% | 6954 |
|
|
2019
Q3 | $13K | Buy |
810
+247
| +44% | +$4.81K | ﹤0.01% | 7018 |
|
|
2019
Q2 | $14K | Buy |
563
+561
| +28,050% | +$17.5K | ﹤0.01% | 6866 |
|
|
2019
Q1 | $0 | Sell |
2
-126
| -98% | -$5.18K | ﹤0.01% | 8327 |
|
|
2018
Q4 | $5K | Buy |
128
+102
| +392% | +$8.6K | ﹤0.01% | 7578 |
|
|
2018
Q3 | $4K | Sell |
26
-31
| -54% | -$4.59K | ﹤0.01% | 7597 |
|
|
2018
Q2 | $7K | Sell |
57
-349
| -86% | -$52.8K | ﹤0.01% | 7363 |
|
|
2018
Q1 | $100K | Sell |
406
-624
| -61% | -$176K | ﹤0.01% | 5223 |
|
|
2017
Q4 | $285K | Sell |
1,030
-830
| -45% | -$317K | ﹤0.01% | 4668 |
|
|
2017
Q3 | $753K | Buy |
1,860
+491
| +36% | +$256K | ﹤0.01% | 3926 |
|
|
2017
Q2 | $811K | Buy |
1,369
+1,367
| +68,350% | +$799K | ﹤0.01% | 3786 |
|
|
2017
Q1 | $1K | Sell |
2
-3
| -60% | -$1.07K | ﹤0.01% | 7490 |
|
|
2016
Q4 | $1K | Sell |
5
-6
| -55% | -$1.36K | ﹤0.01% | 7664 |
|
|
2016
Q3 | $3K | Hold |
11
| – | – | ﹤0.01% | 7322 |
|
|
2016
Q2 | $3K | Sell |
11
-72
| -87% | -$25.3K | ﹤0.01% | 7357 |
|
|
2016
Q1 | $36K | Buy |
83
+4
| +5% | +$1.5K | ﹤0.01% | 5753 |
|
|
2015
Q4 | $39K | Buy |
79
+14
| +22% | +$10.1K | ﹤0.01% | 6066 |
|
|
2015
Q3 | $77K | Buy |
65
+50
| +333% | +$76.6K | ﹤0.01% | 5449 |
|
|
2015
Q2 | $26K | Buy |
15
+6
| +67% | +$9.33K | ﹤0.01% | 6632 |
|
|
2015
Q1 | $11K | Sell |
9
-32
| -78% | -$37.9K | ﹤0.01% | 7586 |
|
|
2014
Q4 | $41K | Buy |
+41
| New | +$41.1K | ﹤0.01% | 6741 |
|
Other funds holding VYNT
UBS Group's VYNT Position: Q2 2023 in Review
UBS Group sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 5,463 shares — an estimated $3.17K sold.
UBS Group first reported a position in VYNT in Q4 2014 and held it in 32 quarters. The position peaked at $811K in Q2 2017. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.
- UBS Group reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 5,463 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $3.17K.
- UBS Group first reported a position in Vyant Bio, Inc. Common Stock in Q4 2014 and held it in 32 quarters.
- UBS Group's Vyant Bio, Inc. Common Stock position peaked at $811K in Q2 2017.
- 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.